Skip to main content
Back
PPTDF logo

PeptiDream Inc.

Data quality: 100%
Oversold
PPTDF
OTC Healthcare Biotechnology
$7.75
$0.00 (0.00%)
Mkt Cap: 1.00B
Day Range
$7.75 $8.30
52-Week Range
$7.75 $17.85
Volume
100
50D / 200D Avg
$9.79 / $11.04
Prev Close
$7.75

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -0.3 0.4
P/B 0.0 2.9
ROE % -6.9 3.7
Net Margin % -20.2 3.9
Rev Growth 5Y % 18.6 10.0
D/E 0.3 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $220.23
$120.98 – $342.51
79 B 1
FY2029 $141.75
$77.87 – $220.45
61 B 1
FY2028 $118.08
$64.87 – $183.64
53 B 1

Key Takeaways

Revenue grew 18.61% annually over 5 years — strong growth
Earnings declined -124.99% over the past year
Debt/Equity of 0.33 — conservative balance sheet
Negative free cash flow of -14.93B
PEG of 0.54 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 78.90%

Growth

Revenue Growth (5Y)
18.61%
Revenue (1Y)-60.29%
Earnings (1Y)-124.99%
FCF Growth (3Y)N/A

Quality

Return on Equity
-6.93%
ROIC-5.44%
Net Margin-20.24%
Op. Margin-26.86%

Safety

Debt / Equity
0.33
Current Ratio1.66
Interest Coverage-9.94

Valuation

P/E Ratio
-0.27
P/B Ratio0.02
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -60.29% Revenue Growth (3Y) -16.91%
Earnings Growth (1Y) -124.99% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 18.61% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 18.54B Net Income (TTM) -3.75B
ROE -6.93% ROA -4.87%
Gross Margin 40.61% Operating Margin -26.86%
Net Margin -20.24% Free Cash Flow (TTM) -14.93B
ROIC -5.44% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.33 Current Ratio 1.66
Interest Coverage -9.94 Dividend Yield 0.00%
Valuation
P/E Ratio -0.27 P/B Ratio 0.02
P/S Ratio 0.05 PEG Ratio 0.54
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.00B Enterprise Value -10.65B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2022 FY2021 FY2020
Revenue 18.54B 46.68B 26.85B 9.37B 11.68B
Net Income -3.75B 15.01B 7.55B 3.61B 4.45B
EPS (Diluted) -29.80 115.68 58.14 19.81 34.26
Gross Profit 7.53B 34.50B 18.11B 7.01B 9.53B
Operating Income -4.98B 21.11B 8.98B 4.42B 6.99B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2022 FY2021 FY2020
Total Assets 77.10B 92.77B 63.87B 26.62B 26.27B
Total Liabilities 25.53B 36.01B 31.82B 1.62B 5.05B
Shareholders' Equity 51.57B 56.76B 32.04B 25.00B 21.22B
Total Debt 17.06B 19.63B 21.05B 0.0 0.0
Cash & Equivalents 28.71B 48.12B 5.25B 11.75B 7.15B
Current Assets 38.95B 57.21B 25.07B 13.86B 15.64B
Current Liabilities 23.44B 18.41B 11.03B 1.27B 4.71B